July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Long-term rescue of vision with antisense oligonucleotides in a mouse model of Usher syndrome
Author Affiliations & Notes
  • Jennifer J Lentz
    Neuroscience Center, LSUHSC, New Orleans, Louisiana, United States
  • Russell Amato
    Neuroscience Center, LSUHSC, New Orleans, Louisiana, United States
  • Robert Rosencrans
    Neuroscience Center, LSUHSC, New Orleans, Louisiana, United States
  • Francine Jodelka
    Cell Biology and Anatomy, Rosalind Franklin University, North Chicago, Illinois, United States
  • Frederic F Depreux
    Cell Biology and Anatomy, Rosalind Franklin University, North Chicago, Illinois, United States
  • Bhagwat V Alapure
    Neuroscience Center, LSUHSC, New Orleans, Louisiana, United States
  • Nicolas G Bazan
    Neuroscience Center, LSUHSC, New Orleans, Louisiana, United States
  • Frank Rigo
    Ionis Pharmaceuticals, Inc, Carlsbad, California, United States
  • Michelle Hastings
    Cell Biology and Anatomy, Rosalind Franklin University, North Chicago, Illinois, United States
  • Footnotes
    Commercial Relationships   Jennifer Lentz, None; Russell Amato, None; Robert Rosencrans, None; Francine Jodelka, None; Frederic Depreux, None; Bhagwat Alapure, None; Nicolas Bazan, None; Frank Rigo, Ionis Pharmaceuticals, Inc (E); Michelle Hastings, Ionis Pharmaceuticals, Inc (F)
  • Footnotes
    Support  NIH Grant GM10494, NIH Grant GM103340, Foundation Fighting Blindness, Usher 2020 Foundation
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4523. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jennifer J Lentz, Russell Amato, Robert Rosencrans, Francine Jodelka, Frederic F Depreux, Bhagwat V Alapure, Nicolas G Bazan, Frank Rigo, Michelle Hastings; Long-term rescue of vision with antisense oligonucleotides in a mouse model of Usher syndrome. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4523.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Retinitis pigmentosa (RP) affects 1 in 4000 individuals worldwide, yet there are no effective treatments available. Usher syndrome (Usher) is a form of RP that also includes hearing impairment. Transgenic mice with a mutation in the Ush1c gene (216A), which causes Usher in humans, have retinal dysfunction characteristic of RP, as well as profound hearing and vestibular deficits. We have previously shown that an ASO targeting the 216A mutation rescues hearing and balance in Usher mice. The purpose of this study was to test the effect of an ASO treatment regimen for RP in a mouse model of Usher.

Methods : Various of doses of 216A-targeted ASOs were delivered locally to the eye by intravitreal injection (IVI) in Usher and control-treated littermate mice. ASO localization in retinal cells after IVI was evaluated by immunohistochemistry (IHC) analysis. Ush1c gene and protein expression in the retina was determined by reverse transcription-polymerase chain reaction (RT-PCR) and IHC analyses, respectively. Visual function and retinal structures were evaluated by electroretinogram (ERG) and optical coherence tomography (OCT) imaging analyses, respectively.

Results : IHC analysis shows that IVI delivery of ASOs targets all regions and layers of the retina. RT-PCR analysis of retinal RNA isolated from ASO-treated Usher mice demonstrated a dose-dependent correction in Ush1c splicing. ERG and OCT analysis showed significant improvements in photoreceptor function and structure, respectively, after a single IVI treatment of ASO in neonatal and adult Usher mice compared to control mice. Repeated ASO treatments every three months over the course of a year sustained the therapeutic effect.

Conclusions : Our results show that ASOs delivered locally to the eye can effectively target Ush1c mutations in the retina and the potential for a long-term benefit to vision with ASO treatment in patients who carry this USH1C mutation. These results also demonstrate the efficacy of ASO therapeutics for the treatment of eye diseases in general.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×